COVID-19: India gets two more vaccines CORBEVAX, COVOVAX approved for emergency use authorisation

New Delhi: Union Health Minister Mansukh Mandaviya on Tuesday (December 28, 2021) announced that the Central Drugs Standard Control Organization (CDSCO), which comes under the Ministry of Health and Family Welfare, has granted emergency use authorization to two COVID-19 patients . Approved. Vaccines such as Covovax and Corbevax.

Mandaviya also said on Twitter that an anti-viral drug Molnupiravir has also been approved for restricted use in emergency situations.

CORBEVAX is India’s first indigenously developed RBD protein sub-unit vaccine against COVID-19 and will be made by Hyderabad-based firm Biological-E.

COVOVAX, a nanoparticle vaccine, will be manufactured by Pune-based firm Serum Institute of India.

Molnupiravir, which is an antiviral drug, will be manufactured by 13 companies in the country for restricted use in emergency situations to treat adult patients with COVID-19 who are at high risk of developing the disease.

Mandaviya tweeted, “Prime Minister Narendra Modi ji has led the fight against COVID-19 from the front. All these approvals will further strengthen the global fight against the pandemic. Our pharma industry is an asset to the entire world.”

With this, the number of vaccines that have received emergency use authorization in India has now risen to eight.

So far, Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Zydus Cadila’s ZyCoV-D, Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Zydus Cadila’s ZyCoV-D,cy use authorization.